Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in pediatric generalized Myasthenia Gravis (OLE)
NCT06540144Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Oct 2024; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06540144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540144.